 |
|
Should embryos with a hereditary disorder be transferred if no unaffected embryos are available?
July 08, 2008Barcelona, Spain: The numbers of cycles of preimplantation genetic diagnosis or screening are rising steadily in Europe with over 2,700 reported in 2004 (the most recent year for which data are available). Fertility centres are able to screen for a growing number of genetically related conditions, but what should doctors do if no embryos without the targeted condition are available for transfer and the parents request that affected embryos should be transferred instead?
Ethicist Dr Wybo Dondorp told the 24th annual meeting of the European Society of Human Reproduction and Embryology in Barcelona today (Monday): "Parental requests for transferring affected embryos should not be dismissed beforehand as a sign of irresponsible capriciousness. As the couple's primary wish may be for a child, they may reason that if a non-affected, healthy child is not what they can get, they will also be happy with, and good parents for, a child with a condition they at first intended to avoid. Respect for autonomy at least requires taking such requests seriously, even if, in view of all other considerations, doctors decide not agree to the requests."
Dr Dondorp, who is a senior research fellow at the faculty of Health, Medicine and Life Sciences, department of Health, Ethics and Society at Maastricht University (The Netherlands), said that before couples have preimplantation genetic diagnosis (PGD), fertility clinics should discuss the decision-making process and the particular clinic's policy in their pre-test counselling sessions with prospective parents, so that everyone was clear about what the options were in cases where no unaffected embryos could be obtained.
He said the most important consideration was the welfare of the child, particularly taking into account doctors' professional responsibility "to do no harm". "A high risk of serious harm is a contraindication for transferring affected embryos. The present consensus is that where the classical indications for PGD are concerned, doctors should, as a general rule, not transfer affected embryos where no non-affected ones are available. In pre-test counselling it should be explained that if no non-affected embryos are available, the only options are trying a new cycle or being advised to reconsider one's reproductive plans such as refraining from reproduction, using donor eggs or sperm, or adoption.
"The welfare of the child is closely connected to the classical indication for PGD: a serious disease caused by a single gene mutation for which there are no, or limited, treatments, and, in most cases, presenting early in life. An example is an embryo that is homozygous for cystic fibrosis, where the child will definitely have the disease. In such cases it is inconceivable that doctors would agree to transfer these embryos as it would be at odds with their professional responsibilities."
However, as the use of PGD is being extended increasingly to conditions outside the classical range of indications, transferring affected embryos need not always involve a high risk of serious harm. This is obvious where treatable diseases are concerned, such as MCAD deficiency (where people with a faulty medium-chain acyl-CoA dehydrogenase gene are unable to metabolise fat, but can lead a healthy life by observing a strict diet).
"Things are less clear where PGD for hereditary cancer syndromes is concerned. Debate about this is urgent, as centres are already confronted with parental requests to transfer embryos found to have the targeted mutation (e.g. BRCA1 or BRCA2 genes for hereditary breast cancer) in cases where no non-affected ones turned out to be available. How should they respond? That there seems to be more room here to at least discuss the issue has everything to do with the nature of the conditions in question: serious but later onset, incomplete genetic penetrance (not all individuals with the mutation will also have the disease) and availability of some therapeutic options," said Dr Dondorp.
"In the case of PGD for hereditary cancer, room for manoeuvre will depend on a case-sensitive evaluation of aspects relevant to the 'high risk of serious harm' criterion, also in view of the family history. If this approach is acceptable and if further debate leads centres to decide that they would not categorically rule this out, pre-test information about centre policy should be adapted accordingly. It must be made clear that there may be, with conditions, room for shared decision-making about transferring affected embryos. But that does not amount to leaving it to the parents, as doctors cannot avoid their professional responsibility for the welfare of the future child."
He concluded: "However, professionals may still find it difficult to respond to such requests that lead not only to the deliberate conception of a child in need of special care, but also to the very outcome they set out to prevent when offering PGD to a couple. Is it acceptable to use PGD just for trying to have a better result than one is eventually prepared to accept? This fits in with a wider debate about the morally charged nature of PGD and the proportionality of its uses: is it acceptable to use PGD for avoiding treatable disease, such as MCAD, in the first place?"
Together with Professor Guido de Wert, also from Maastricht University, Dr Dondorp is writing a paper to be published in Europe's leading reproductive medicine journal, Human Reproduction, on these issues. This is the first time ethicists have considered the questions that arise as a result of extending the use of PGD to hereditary symptoms such as cancer and MCAD.
European Society for Human Reproduction and Embryology
He said the most important consideration was the welfare of the child, particularly taking into account doctors' professional responsibility "to do no harm". "A high risk of serious harm is a contraindication for transferring affected embryos. The present consensus is that where the classical indications for PGD are concerned, doctors should, as a general rule, not transfer affected embryos where no non-affected ones are available. In pre-test counselling it should be explained that if no non-affected embryos are available, the only options are trying a new cycle or being advised to reconsider one's reproductive plans such as refraining from reproduction, using donor eggs or sperm, or adoption.
"The welfare of the child is closely connected to the classical indication for PGD: a serious disease caused by a single gene mutation for which there are no, or limited, treatments, and, in most cases, presenting early in life. An example is an embryo that is homozygous for cystic fibrosis, where the child will definitely have the disease. In such cases it is inconceivable that doctors would agree to transfer these embryos as it would be at odds with their professional responsibilities."
However, as the use of PGD is being extended increasingly to conditions outside the classical range of indications, transferring affected embryos need not always involve a high risk of serious harm. This is obvious where treatable diseases are concerned, such as MCAD deficiency (where people with a faulty medium-chain acyl-CoA dehydrogenase gene are unable to metabolise fat, but can lead a healthy life by observing a strict diet).
"Things are less clear where PGD for hereditary cancer syndromes is concerned. Debate about this is urgent, as centres are already confronted with parental requests to transfer embryos found to have the targeted mutation (e.g. BRCA1 or BRCA2 genes for hereditary breast cancer) in cases where no non-affected ones turned out to be available. How should they respond? That there seems to be more room here to at least discuss the issue has everything to do with the nature of the conditions in question: serious but later onset, incomplete genetic penetrance (not all individuals with the mutation will also have the disease) and availability of some therapeutic options," said Dr Dondorp.
"In the case of PGD for hereditary cancer, room for manoeuvre will depend on a case-sensitive evaluation of aspects relevant to the 'high risk of serious harm' criterion, also in view of the family history. If this approach is acceptable and if further debate leads centres to decide that they would not categorically rule this out, pre-test information about centre policy should be adapted accordingly. It must be made clear that there may be, with conditions, room for shared decision-making about transferring affected embryos. But that does not amount to leaving it to the parents, as doctors cannot avoid their professional responsibility for the welfare of the future child."
He concluded: "However, professionals may still find it difficult to respond to such requests that lead not only to the deliberate conception of a child in need of special care, but also to the very outcome they set out to prevent when offering PGD to a couple. Is it acceptable to use PGD just for trying to have a better result than one is eventually prepared to accept? This fits in with a wider debate about the morally charged nature of PGD and the proportionality of its uses: is it acceptable to use PGD for avoiding treatable disease, such as MCAD, in the first place?"
Together with Professor Guido de Wert, also from Maastricht University, Dr Dondorp is writing a paper to be published in Europe's leading reproductive medicine journal, Human Reproduction, on these issues. This is the first time ethicists have considered the questions that arise as a result of extending the use of PGD to hereditary symptoms such as cancer and MCAD.
European Society for Human Reproduction and Embryology
Embryos Current Events and Embryos News RSSDNA barcodes: Creative new uses span health, fraud, smuggling, history, more
The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others.
Tiny injector to speed development of new, safer, cheaper drugs
It's no bigger than a stamp packet but it has the potential to allow rapid development of a new generation of drugs and genetic engineering organisms, and to better control in-vitro fertilization.
Of mice and men: Stem cells and ethical uncertainties
The recent creation of live mice from induced pluripotent stem cells (iPSCs) not only represents a remarkable scientific achievement, but also raises important issues, according to bioethicists at The Johns Hopkins University's Berman Institute of Bioethics.
The skeleton: Size matters
Vertebrates have in common a skeleton made of segments, the vertebrae. During development of the embryo, each segment is added in a time dependent manner, from the head-end to the tail-end: the first segments to be added become the vertebrae of the neck, later segments become the vertebrae with ribs and the last ones the vertebra located in the tail (in the case of a mouse, for example).
Endocrine Society calls for expanded scope and funding for stem cell research
Stem cell research holds great promise for the treatment of millions of Americans with debilitating and possibly fatal diseases.
Researchers discover mechanism that prevents two species from reproducing
Cornell researchers have discovered a genetic mechanism in fruit flies that prevents two closely related species from reproducing, a finding that offers clues to how species evolve.
IVF insurance coverage yields fewer multiple births, Yale researchers find
The proportion of in vitro fertilization (IVF) multiple births was lower in the eight states that provide insurance coverage for couples seeking IVF treatment, primarily due to fewer embryos transferred per cycle.
Identifying the metabolism of a healthy embryo could improve infertility treatment
Embryos that are most likely to result in a pregnancy are crucial to the success of in vitro fertilization (IVF) but are difficult to identify. Researchers at Yale School of Medicine, led by Emre Seli, M.D., are developing a fast, non-invasive test to help assess embryo viability for IVF.
Small mechanical forces have big impact on embryonic stem cells
Applying a small mechanical force to embryonic stem cells could be a new way of coaxing them into a specific direction of differentiation, researchers at the University of Illinois report. Applications for force-directed cell differentiation include therapeutic cloning and regenerative medicine.
Cell death occurs in the same way in plants, animals and humans
Research has previously assumed that animals and plants developed different genetic programs for cell death.
More Embryos Current Events and Embryos News Articles
 |
Embryo: A Defense of Human Life by Robert P. George (Author), Christopher Tollefsen (Author) The bitter national debates over abortion, euthanasia, and stem cell research have created an unbridgeable gap between religious groups and those who insist that faith-based views have no place in public policy. Religious conservatives are so adamantly opposed to stem cell research in particular that President Bush issued the first veto of his presidency over a bill that would have provided federal funding for such research. |
 |
Embryo Starring: Rock Hudson, Barbara Carrera, Diane Ladd, Roddy McDowall, Anne Schedeen Directed By: Ralph Nelson Also With: Fred J. Koenekamp (Cinematographer), Anita Doohan (Producer), Anita Doohan (Writer), Arnold H. Orgolini (Producer), Michael S. Glick (Producer), Sandy Howard (Producer), Jack W. Thomas (Writer) Rock Hudson stars in this science fiction story of an experiment gone very wrong. He plays a scientist who decides to create a human from basic genetic material. The result is lovely Barbara Carrera (the sexy villainess of 'Never Say Never Again') in the role of the creature grown from an embryo. Although beautiful, she displays not only her physical charms but aberrant and definitely homicidal behavior. As she becomes more erratic, the enamored doctor is faced with perhaps destroying his own creation. Roddy McDowall and Diane Ladd also star in this unusual tale mixing sex with science. Running time: Approx. 106 minutes Includes the original theatrical trailer! Approx. 2 minutes Bonus Material: Beautiful women turned into monsters (and vice versa!) has been a popular theme in horror... |
 |
Steig Aus by Embryo Founded by Christian Burchard (drums, marimba, vibraphone) and still going strong almost 38 years later, Embryo are an excellent example of fusion music from 1973 and further demonstrate the vision of diversity the Brain label founders had. Aided by Dave King and Joerg Evers on bass, the famous Mal Waldron on electric piano, Roman Bunka on guitar, Jimmy Jackson on organ and Mellotron and Edgar Hoffmann on violin, Steig Aus is built of 3 long and wonderful tracks. Steig Aus is another "must own" record, not only for Krautrock collectors but for lovers of fine music in general. |
 |
Manipulating the Mouse Embryo: A Laboratory Manual, Third Edition by Andras Nagy (Author), Marina Gertsenstein (Author), Kristina Vintersten (Author), Richard Behringer (Author) Regarded as the "Bible" of mammalian embryo manipulation techniques since the 1986 publication of the first edition of Manipulating the Mouse Embryo: A Laboratory Manual, the third edition of this essential laboratory resource has now been completely reorganized, rewritten, and updated by a new cast of authors. The result is a compilation of new, cutting–-edge protocols that include embryonic stem cell production and genetic manipulation, mouse chimeras, mouse cloning, assisted reproduction strategies (including intracytoplasmic sperm injection and in vitro fertilization), whole embryo culture systems, electroporation, embryo and gamete cryopreservation and rederivation, and gene expression, as well as more extensive background information on the use of these techniques. The... |
 |
Embryo Starring: Rock Hudson, Barbra Carrera, Dianne Ladd, Roddy McDowell Directed By: Ralph Nelson |
 |
The Triumph of the Embryo by Lewis Wolpert PhD (Author) Of the great mysteries that face modern biologists, one of the most intriguing concerns the development of the microscopic embryo into exceedingly complex plants and animals--into roses and cacti, elephants and blue whales, apes and human beings. How does one cell give rise to so many millions of cells? How do they divide so as to form hearts, brains, eyes, and ears? Where in this pin-head-sized object is all this information encoded? Now, in The Triumph of the Embryo, British biologist Lewis Wolpert treats general readers to a lucid tour of embryology, offering the latest theories in this fascinating field. Like the best scientist-authors, Wolpert's writing is filled with rich and unusual examples, metaphors, and descriptions. Nor does he hesitate to move beyond his overall... |
 |
Steig Aus by Embryo Founded by Christian Burchard (drums, marimba, vibraphone) and still going strong almost 38 years later, Embryo are an excellent example of fusion music from 1973 and further demonstrate the vision of diversity the Brain label founders had. Aided by Dave King and Joerg Evers on bass, the famous Mal Waldron on electric piano, Roman Bunka on guitar, Jimmy Jackson on organ and Mellotron and Edgar Hoffmann on violin, Steig Aus is built of 3 long and wonderful tracks. Steig Aus is another "must own" record, not only for Krautrock collectors but for lovers of fine music in general. |
 |
Embryos and Idiots by Larissa Szporluk (Author) "This is poetry both luscious and rigorous."-Lynn Emanuel This latest collection from the young but already established luminary Larissa Szporluk is cause for celebration. Szporluk has proven once again that she not only deserves her elevated status in the poetry world, but reinvents and advances it with each new collection. This is spare, sly, seductive, and haunting poetry that resonates long after the rustle of the page. Szporluk has an uncanny ability to hone her words until their edges slice like small, deep paper cuts, whittling away at the human experience, searching for the truth of things. Despite her three previously published-and much heralded-works, this visionary poet continues to innovate. She remains completely unpredictable, as if these... |
 |
Embryo Starring: Rock Hudson, Barbara Carrera, Diane Ladd, Roddy McDowall, Anne Schedeen Directed By: Ralph Nelson Also With: Anita Doohan (Producer), Michael S. Glick (Producer), Sandy Howard (Producer), Arnold H. Orgolini (Producer) |
 |
What You Want Embryo Version The Emperor MacHine (Primary Contributor) |
| © 2009 BrightSurf.com |